表紙
市場調查報告書

全球頭孢菌素醫藥品市場:世代,種類,製劑,適應症,流通管道,各地區 - 規模,佔有率,趨勢,預測

Cephalosporin Drugs Market, By Generation, By Type, By Formulation, By Indication, By Distribution Channel, and By Region - Size, Share, Trends, and Forecast 2019 - 2026

出版商 Coherent Market Insights 商品編碼 906228
出版日期 內容資訊 英文 236 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球頭孢菌素醫藥品市場:世代,種類,製劑,適應症,流通管道,各地區 - 規模,佔有率,趨勢,預測 Cephalosporin Drugs Market, By Generation, By Type, By Formulation, By Indication, By Distribution Channel, and By Region - Size, Share, Trends, and Forecast 2019 - 2026
出版日期: 2019年07月23日內容資訊: 英文 236 Pages
簡介

本報告提供全球頭孢菌素醫藥品的相關調查,提供市場機會和趨勢,成長及阻礙因素,世代·種類·製劑·適應症·流通管道·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查的目的及假設

  • 調查目的
  • 假設
  • 簡稱

第2章 市場概要

  • 報告的說明
    • 市場定義及範圍
  • 摘要整理
    • 各世代
    • 各類型
    • 各製劑
    • 各適應症
    • 各流通管道
    • 各地區
  • COM (Coherent Opportunity Map)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的開發
  • 領導品牌分析
  • 償付方案
  • 流行病學分析
  • 波特的五力分析
  • 開發平台分析
  • 開關分析
  • 網站連鎖分析

第4章 全球市場

  • 抗生素抗性趨勢:各國

第5章 頭孢菌素醫藥品的全球市場:各世代

  • 簡介
  • 第1代
  • 第2代
  • 第3代
  • 第4代
  • 第5代

第6章 頭孢菌素醫藥品的全球市場:各類型

  • 簡介
  • 品牌頭孢菌素
  • 非專利頭孢菌素

第7章 頭孢菌素醫藥品的全球市場:各製劑

  • 簡介
  • 口服
  • 注射

第8章 頭孢菌素醫藥品的全球市場:各適應症

  • 簡介
  • 呼吸系統感染疾病
  • 皮膚感染
  • 耳朵感染疾病
  • 細菌感染
  • 尿道感染
  • 性感染疾病
  • 鼻竇感染疾病
  • 外科的預防
  • 其他(腦膜炎,急性腹部感染,骨盆感染)

第9章 頭孢菌素醫藥品的全球市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第10章 頭孢菌素醫藥品的全球市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第11章 競爭情形

  • 企業簡介
    • Merck & Co. Inc.
    • GlaxoSmithKline plc.
    • Pfizer Inc.
    • Allergan plc.
    • Abbott Laboratories
    • Basilea Pharmaceutica Ltd.
    • Sanofi S.A.
    • F. Hoffmann-La Roche AG
    • Lupin Limited
    • Teva Pharmaceutical Industries Ltd.
    • B. Braun Melsungen AG
  • 分析師的見解

第12章 章節

  • 參照資料
  • 調查方法
  • 關於Coherent Market Insight
目錄

Title:
Cephalosporin Drugs Market, By Generation (First-generation, Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin), By Type (Branded Cephalosporin Drugs and Generic Cephalosporin Drugs), By Formulation (Oral (Tablets, Capsules, and Liquid) and Injection), By Indication (Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and Others (Meningitis, Acute Abdomen Infection, and Pelvic infection)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast 2019 - 2026.

Cephalosporin drugs are a group of broad-spectrum, semi-synthetic beta-lactam antibiotics generally used for the treatment of bacterial infections such as bacterial meningitis, otitis media, pneumonia, tuberculosis, upper respiratory tract infection, eye infections, sinusitis, urinary tract infections, skin infections, and sexually transmitted diseases. Most commonly used cephalosporin are cephalexin, ceftriaxone, cefixime, cefdinir, and cefaclor. The cephalosporin drugs market holds a huge potential in the sub-Saharan countries of Africa such as Ethiopia, Ghana, Nigeria, and Senegal, as these countries have high prevalence of bacterial infections due to underdeveloped healthcare facilities and infrastructure. For instance, according to the World Health Organization's (WHO) report of February 2018, the highest burden of this disease is in the belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.

Market Dynamics:

Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015.

However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.

Key features of the study:

  • This report provides in-depth analysis of the cephalosporin drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 - 2026, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cephalosporin drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global cephalosporin drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for cephalosporin drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Cephalosporin Drugs Market, By Generation:
    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
  • Global Cephalosporin Drugs Market, By Type:
    • Branded Cephalosporin Drugs
    • Generic Cephalosporin Drugs
  • Global Cephalosporin Drugs Market, By Formulation:
    • Oral
      • Tablets
      • Capsules
      • Liquid
    • Injection
  • Global Cephalosporin Drugs Market, By Indication:
    • Respiratory Tract Infection
    • Skin Infection
    • Ear Infection
    • Bacterial Infection
    • Urinary Tract Infection
    • Sexually Transmitted Infection
    • Sinus Infection
    • Surgical Prophylaxis
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
  • Global Cephalosporin Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Cephalosporin Drugs Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Generation:
    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
      • By Type:
    • Branded Cephalosporin Drugs
    • Generic Cephalosporin Drugs
      • By Formulation:
    • Oral
  • Tablets
  • Capsules
  • Liquid
    • Injection
      • By Indication:
    • Respiratory Tract Infection
    • Skin Infection
    • Ear Infection
    • Bacterial Infection
    • Urinary Tract Infection
    • Sexually Transmitted Infection
    • Sinus Infection
    • Surgical Prophylaxis
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Generation:
    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
      • By Type:
    • Branded Cephalosporin Drugs
    • Generic Cephalosporin Drugs
      • By Formulation:
    • Oral
  • Tablets
  • Capsules
  • Liquid
    • Injection
      • By Indication:
    • Respiratory Tract Infection
    • Skin Infection
    • Ear Infection
    • Bacterial Infection
    • Urinary Tract Infection
    • Sexually Transmitted Infection
    • Sinus Infection
    • Surgical Prophylaxis
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Generation:
    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
      • By Type:
    • Branded Cephalosporin Drugs
    • Generic Cephalosporin Drugs
      • By Formulation:
    • Oral
  • Tablets
  • Capsules
  • Liquid
    • Injection
      • By Indication:
    • Respiratory Tract Infection
    • Skin Infection
    • Ear Infection
    • Bacterial Infection
    • Urinary Tract Infection
    • Sexually Transmitted Infection
    • Sinus Infection
    • Surgical Prophylaxis
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Generation:
    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
      • By Type:
    • Branded Cephalosporin Drugs
    • Generic Cephalosporin Drugs
      • By Formulation:
    • Oral
  • Tablets
  • Capsules
  • Liquid
    • Injection
      • By Indication:
    • Respiratory Tract Infection
    • Skin Infection
    • Ear Infection
    • Bacterial Infection
    • Urinary Tract Infection
    • Sexually Transmitted Infection
    • Sinus Infection
    • Surgical Prophylaxis
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Generation:
    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
      • By Type:
    • Branded Cephalosporin Drugs
    • Generic Cephalosporin Drugs
      • By Formulation:
    • Oral
  • Tablets
  • Capsules
  • Liquid
    • Injection
      • By Indication:
    • Respiratory Tract Infection
    • Skin Infection
    • Ear Infection
    • Bacterial Infection
    • Urinary Tract Infection
    • Sexually Transmitted Infection
    • Sinus Infection
    • Surgical Prophylaxis
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Generation:
    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
      • By Type:
    • Branded Cephalosporin Drugs
    • Generic Cephalosporin Drugs
      • By Formulation:
    • Oral
  • Tablets
  • Capsules
  • Liquid
    • Injection
      • By Indication:
    • Respiratory Tract Infection
    • Skin Infection
    • Ear Infection
    • Bacterial Infection
    • Urinary Tract Infection
    • Sexually Transmitted Infection
    • Sinus Infection
    • Surgical Prophylaxis
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Merck & Co. Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • GlaxoSmithKline plc.
    • Pfizer Inc.
    • Allergan plc.
    • Abbott Laboratories
    • Basilea Pharmaceutica Ltd.
    • Sanofi S.A.
    • F. Hoffmann-La Roche AG
    • Lupin Limited
    • Teva Pharmaceutical Industries Ltd.
    • B. Braun Melsungen AG

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Generation
    • Market Snippet, By Type
    • Market Snippet, By Formulation
    • Market Snippet, By Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Major Brand Analysis
  • Reimbursement Scenario
  • Epidemiology Analysis
  • Porter's Five Forces Model
  • Pipeline Analysis
  • Switch Analysis
  • Site Chain Analysis

4. Global Cephalosporin Drugs Market

  • Antibiotic Resistance Trends By Country

5. Global Cephalosporin Drugs Market, By Generation, 2019 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
  • First-generation Cephalosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Second-generation Cephalosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Third-generation Cephalosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Fourth-generation Cephalosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Fifth-generation Cephalosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)

6. Global Cephalosporin Drugs Market, By Type, 2019 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
  • Branded Cephalosporin Drugs
    • Market Share Analysis, 2019 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
  • Generic Cephalosporin Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)

7. Global Cephalosporin Drugs Market, By Formulation, 2019 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
  • Oral
    • Market Share Analysis, 2019 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
    • Tablets
    • Capsules
    • Liquid
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)

8. Global Cephalosporin Drugs Market, By Indication, 2019 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
  • Respiratory Tract Infection
    • Market Share Analysis, 2019 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
  • Skin Infection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Ear Infection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Bacterial Infection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Urinary Tract Infection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Sexually Transmitted Infection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Sinus Infection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Surgical Prophylaxis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)

9. Global Cephalosporin Drugs Market, By Distribution Channel, 2019 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2026, (US$ Million)

10. Global Cephalosporin Drugs Market, By Region, 2019 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2019 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2018 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Generation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Type, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Formulation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Indication, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Generation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Type, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Formulation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Indication, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Generation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Type, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Formulation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Indication, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Generation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Type, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Formulation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Indication, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Generation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Type, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Formulation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Indication, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2019 - 2026, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Generation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Type, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Formulation, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Indication, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

11. Competitive Landscape

  • Company Profiles
    • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Allergan plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Abbott Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Basilea Pharmaceutica Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Lupin Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • B. Braun Melsungen AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

12. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top